Whereas in humans with CAPS, anti‐IL‐1β therapy has proved efficacious and can mitigate most of the inflammatory symptoms (Booshehri & Hoffman, 2019), the situation in complex diseases, in which the appearance of triggers activates NLRP3, is likely different. This evidence concerns the gene NLRP3 and cryopyrin-associated periodic syndrome.